The U.S. Food and Drug Administration has approved a new daily oral medication for chronic weight management, offering a convenient alternative to weekly injections. The drug, Foundayo (orforglipron) from Eli Lilly, is approved for adults with obesity or who are overweight and have at least one related health condition, such as hypertension or heart disease.
This approval makes Foundayo the second oral GLP-1 receptor agonist for weight loss, following Novo Nordisk's Wegovy pill in late 2025. The development marks a significant shift toward more accessible formulations of a drug class previously dominated by injectables like Zepbound and Wegovy. Foundayo works by targeting a different GLP-1 hormone than its injectable counterparts. As a small molecule, it is absorbed quickly, meaning patients do not need to restrict food or drink after taking it, a requirement for some other oral options.
In pivotal trials, participants taking Foundayo lost an average of 11% of their body weight, or about 25 pounds, over more than a year. This compared to an average loss of 5.3 pounds in the placebo group. While the weight loss efficacy is somewhat less than the Wegovy pill's reported 16-17%, the new option's daily pill form and different mechanism may suit different patient preferences. The drug will be available in six doses, with patients typically starting low and titrating up under medical supervision.
Company executives position Foundayo as a potential foundational therapy. "We see Foundayo as a foundational GLP-1 therapy," said Eli Lilly CEO David Ricks, noting studies suggest it could be an effective maintenance treatment after initial weight loss with injectables. The company plans to seek additional FDA approvals for conditions like sleep apnea and hypertension. The side effect profile is similar to other GLP-1 drugs, including gastrointestinal issues like nausea and constipation, and a rare increased risk of thyroid cancer.
Accessibility and cost are central to the rollout. Eli Lilly has agreed with the White House to offer initial doses at $149 a month for uninsured individuals and certain Medicare beneficiaries with diabetes. A broader Medicare program starting later this summer could lower the cost to $50 a month for those with obesity-related conditions. For the highest dose, a company program caps the self-pay cost at $299 monthly. Insured patients using a savings card are expected to pay no more than $25 per prescription.
Approved under an expedited FDA review program, Foundayo will be available in pharmacies within a week. With obesity affecting an estimated 100 million Americans, health officials and the company view oral therapies as a critical step toward broader public health solutions. "This is a population health problem and it needs a population health solution," said Dr. Dan Skovronsky, Lilly's chief scientific officer. The arrival of this new pill significantly expands the toolkit available to patients and doctors in managing weight and its related health risks.